Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma

NCT02260492 is registered in ClinicalTrials.gov with Oriel Therapeutics as lead sponsor.

NCT NCT02260492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02260492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Lead sponsor
Oriel Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2014
Completion date
July 31, 2015
Enrollment
879 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

asthma